NEW YORK – Twist Bioscience said on Thursday that it has priced a $100 million public stock offering at $33 per share.
The firm is offering approximately 3 million share of common stock. JP Morgan, Cowen and Company, and Evercore Group are acting as joint book-running managers and Robert W. Baird is acting as lead manager. Twist will grant the underwriters an option to purchase up to an additional 454,545 shares at the public offering price, less the underwriting discount and commissions.
In a statement, Twist said it intends to use the proceeds to invest in R&D and its commercial organization and global expansion, to expand production capacity, and for working capital and general corporate purposes. Twist added that it may use a portion of the proceeds "to in-license, acquire, or invest in complementary businesses or products."
In morning trading on the Nasdaq, shares of Twist were up 2 percent at $37.80.
Twist expects the offering to close on or about June 8.